The Medtech & Pharma Platform Association (MPP) wishes to respectfully draw attention to a series of persistent challenges that continue to hinder the effective and proportionate functioning of the European Unions regulatory framework governing medical devices and in vitro diagnostics.
MPP
Medtech & Pharma Platform Association
Industry association · Switzerland · EU Transparency Register 234427831877-10
8
positions filed
in the 665 files tracked
6
legislative files
of 665 tracked
6
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1518 trade and business associations on this site, they rank #518 by legislative files engaged, a count of participation, not a measure of influence.
0.8
declared lobbying FTE
self-declared
€200K+
declared costs / yr (floor)
0
EP accreditations
as declared to the register
2018
in the register since
- Register category
- Trade and business associations
- Head office
- Basel, Switzerland
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Medtech in PolicySpeak: request access →
Work at Medtech & Pharma Platform Association? so we know who speaks for it.
Their record over time
Medtech & Pharma Platform Association filed 8 positions between 27 Apr 2021 and 23 Jan 2026, across 6 of the 665 legislative files tracked here, attaching a full position paper 6 times.
2021 · 2 filed2023 · 3 filed2025 · 2 filed2026 · 1 filed
What they argued
The Medtech & Pharma Platform Association (MPP) welcomes the proposals objectives to improve the availability and accessibility of medicinal products throughout the EU and support industry competitiveness. We would like to propose amendments on points which are of importance for products combining medicines and medical devices including in-vitro diagnostics and therefore fall under the scope of both the medicinal…
The Medtech & Pharma Platform Association (MPP) welcomes the proposals objectives to improve the availability and accessibility of medicinal products throughout the EU and support industry competitiveness. We would like to propose amendments on points which are of importance for products combining medicines and medical devices including in-vitro diagnostics and therefore fall under the scope of both the medicinal…
To whom it may concern, The Medtech & Pharma Platform Association (MPP) is writing to you to share its views on the European Commission’s combined roadmap/inception impact assessment on the evaluation and revision of the general pharmaceutical legislation. MPP is fully supportive of the points laid out in the evaluation roadmap.
The not-for-profit MPP Association welcomes the European Commission proposal for a Regulation laying down rules on AI. MPP supports efforts to optimize the regulatory framework to create the right conditions for healthcare innovation. We are the opinion that risk categories for AI provide a useful base for the regulation of AI.
The Medtech & Pharma Platform Association (MPP) brings together companies from the pharmaceutical, MedTech, Diagnostics, and Tech sectors to advance combined products, i.e. solutions that integrate drugs, devices, diagnostics, and digital technologies for medical purposes.
The Medtech & Pharma Platform Association (MPP) is writing to you to share its views on the European Commissions proposal regarding the transition periods of the Medical Devices Regulation (MDR) and In Vitro Diagnostics Regulation (IVDR). Overall, the MPP supports and welcomes the proposal, which is crucial to ensure the continued supply of products to patients.
The Medtech & Pharma Platform Association (MPP) welcomes the proposed EU Implementing Regulation establishing harmonised quality management and procedural requirements for conformity assessment activities performed by notified bodies. We consider the introduction of requirements for reliable quotations, predictable timelines, and transparent monitoring of both timelines and costs to be a positive step.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Medtech & Pharma Platform Association next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 151.
Is this your organization?
Everything on this page comes from Medtech & Pharma Platform Association’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.